These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 15799211)

  • 81. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial.
    Speroff L; Rowan J; Symons J; Genant H; Wilborn W
    JAMA; 1996 Nov; 276(17):1397-403. PubMed ID: 8892714
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Effect of microdose transdermal 17beta-estradiol compared with raloxifene in the prevention of bone loss in healthy postmenopausal women: a 2-year, randomized, double-blind trial.
    Schaefers M; Muysers C; Alexandersen P; Christiansen C
    Menopause; 2009; 16(3):559-65. PubMed ID: 19423999
    [TBL] [Abstract][Full Text] [Related]  

  • 83. A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss. Transdermal Estradiol Investigator Group.
    Weiss SR; Ellman H; Dolker M
    Obstet Gynecol; 1999 Sep; 94(3):330-6. PubMed ID: 10472854
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Efficacy and safety of Menorest (50 mikrog/day) compared to Premarin 0.625 mg in the treatment of menopausal symptoms and the prevention of bone loss, in menopausal women. A single-center, comparative, randomized, double-blind, double-dummy study.
    Studd JW; MacCarthy K; Zamblera D; Dain MP
    Scand J Rheumatol Suppl; 1996; 103():89-90. PubMed ID: 8966497
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Endometrial histology and bleeding patterns in post-menopausal women taking sequential, combined estradiol and dydrogesterone.
    Ferenczy A; Gelfand MM
    Maturitas; 1997 Apr; 26(3):219-26. PubMed ID: 9147354
    [TBL] [Abstract][Full Text] [Related]  

  • 86. 17beta-estradiol (1 mg/day) continuously combined with dydrogesterone (5, 10 or 20 mg/day) increases bone mineral density in postmenopausal women.
    Stevenson JC; Teter P; Lees B
    Maturitas; 2001 Apr; 38(2):197-203. PubMed ID: 11306209
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study.
    Alexandersen P; Riis BJ; Christiansen C
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3013-20. PubMed ID: 10487657
    [TBL] [Abstract][Full Text] [Related]  

  • 88. A placebo-controlled trial of ethinyl oestradiol and norethisterone in climacteric women.
    Nordin BE; Jones MM; Crilly RG; Marshall DH; Brooke R
    Maturitas; 1980 Oct; 2(3):247-51. PubMed ID: 7003315
    [TBL] [Abstract][Full Text] [Related]  

  • 89. One-year endometrial safety evaluation of a continuous combined transdermal matrix patch delivering low-dose estradiol-norethisterone acetate in postmenopausal women.
    Samsioe G; Dvorak V; Genazzani AR; Hamann B; Heikkinen J; Mueck AO; Suzin J; Kawakami FT; Ferreira A; Sun D; Arguinzoniz M
    Maturitas; 2007 Jun; 57(2):171-81. PubMed ID: 17317046
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Tolerability and consistency of effect of zolmitriptan nasal spray in a long-term migraine treatment trial.
    Dowson AJ; Charlesworth BR; Purdy A; Becker WJ; Boes-Hansen S; Färkkilä M
    CNS Drugs; 2003; 17(11):839-51. PubMed ID: 12921494
    [TBL] [Abstract][Full Text] [Related]  

  • 91. The menopause: benefits and risks of estrogen-progestogen replacement therapy.
    Gambrell RD
    Fertil Steril; 1982 Apr; 37(4):457-74. PubMed ID: 7040116
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Endometrial response in estrogen replacement therapy quarterly combined with a progestogen.
    Boerrigter PJ; van de Weijer PH; Baak JP; Fox H; Haspels AA; Kenemans P
    Maturitas; 1996 May; 24(1-2):63-71. PubMed ID: 8794436
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Efficacy of biorhythmic transdermal combined hormone treatment in relieving climacteric symptoms: a pilot study.
    Formby B; Schmidt F
    Int J Gen Med; 2011 Feb; 4():159-63. PubMed ID: 21475623
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Safety and acceptability of intravaginal rings releasing estradiol and progesterone.
    Hull ML; Stuckey B; Hartman K; Zack N; Thurman A; Friend DR
    Climacteric; 2023 Oct; 26(5):465-471. PubMed ID: 37054722
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Estradiol-intranasal: a review of its use in the management of menopause.
    Dooley M; Spencer CM; Ormrod D
    Drugs; 2001; 61(15):2243-62. PubMed ID: 11772138
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Spotlight on estradiol and norgestimate as hormone replacement therapy in postmenopausal women.
    Curran MP; Wagstaff AJ
    Treat Endocrinol; 2002; 1(2):127-9. PubMed ID: 15765628
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Estradiol and norgestimate: a review of their combined use as hormone replacement therapy in postmenopausal women.
    Curran MP; Wagstaff AJ
    Drugs Aging; 2001; 18(11):863-85. PubMed ID: 11772126
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Efficacy and acceptability of intranasal 17 beta-oestradiol for menopausal symptoms: randomised dose-response study. Aerodiol Study Group.
    Studd J; Pornel B; Marton I; Bringer J; Varin C; Tsouderos Y; Christiansen C
    Lancet; 1999 May; 353(9164):1574-8. PubMed ID: 10334256
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Spotlight on estradiol-intranasal in the management of menopause.
    Dooley M; Spencer CM; Ormrod D
    Treat Endocrinol; 2002; 1(3):191-4. PubMed ID: 15799211
    [TBL] [Abstract][Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.